Half-Year 2022 Financial and Clinical Trials Update
Vabysmo (faricimab)
Bispecific antibody to simultaneously bind Ang-2 and VEGF-A
Roche
Indication
Macular edema (ME) secondary to branch retinal vein occlusion (RVO)
Macular edema (ME) secondary to central retinal vein occlusion (RVO)
Phase/study
# of patients
Design
Primary endpoint
Status
CT Identifier
"
ARM A: Faricimab, q4w/PTI
ARM B: Aflibercept, q4w
Phase III
BALATON
N=570
Change from baseline in BCVA at week 24
"
FPI Q1 2021
Recruitment completed Q1 2022
NCT04740905
ARM A: Faricimab, q4w/PTI
ARM B: Aflibercept, q4w
Phase III
COMINO
N=750
"
☐
■ Change from baseline in BCVA at week 24
FPI Q1 2021
Recruitment completed Q1 2022
PTI=Personalized Treatment Interval; BCVA=best corrected visual acuity; Ang-2-Angiopoietin-2; VEGF-Vascular endothelial growth factor
NCT04740931
123
OphthalmologyView entire presentation